Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14852726 | 0.90 | OPRM1 (0.55) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL16131234 | 0.90 | OPRM1 (0.55) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL12091233 | 0.86 | OPRM1 (0.56) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL16015640 | 0.84 | OPRM1 (0.53) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL12934538 | 0.84 | OPRM1 (0.53) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL20170649 | 0.81 | OPRM1 (0.54) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL16509912 | 0.81 | OPRM1 (0.54) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL18973514 | 0.79 | OPRM1 (0.53) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL20170709 | 0.79 | OPRM1 (0.51) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| SCHEMBL20170677 | 0.78 | OPRM1 (0.50) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010412-A1 | Process for the Synthesis of Substituted Morphinans | ALKERMES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010412-A1 | Process for the Synthesis of Substituted Morphinans | CYP1B1, DHPS, CYP4B1 | OPRM1 251/4885OPRD1 1176/4885OPRK1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.